



Roskilde, 21 December 2004

Press Release

Nycomed and ZLB Behring agreement for Beriplast® P Combi-Set

Nycomed and ZLB Behring today announced the signing of a ten-year market and distribution agreement for Beriplast® P Combi-Set, a wound healing product manufactured by ZLB Behring. The agreement grants Nycomed the exclusive rights to market the product throughout Europe.

Beriplast® P Combi-Set is a fibrin sealant product used in numerous surgical procedures. Fibrin sealants may be sprayed onto wounds or applied otherwise to reduce blood loss during surgery or to seal tissue surfaces. The product mimics the final steps of the blood coagulation cascade and forms a dense, strong cross-linked fibrin mesh to seal wounds.

"We are pleased to broaden our relationship with Nycomed with this agreement for wider distribution of Beriplast® P Combi-Set in Europe," said Paul Walton, Senior Vice President of Business Development at ZLB Behring. "This agreement will enable a larger population of surgeons to gain access to an effective surgical sealant option for their patients."

"Beriplast® P Combi-Set is a perfect fit with Nycomed's growing hospital specialist portfolio and our position within tissue management," said Håkan Björklund, Nycomed CEO. "Together with TachoSil® launched earlier in 2004 we now have a compelling offer of innovative products to surgeons across Europe. Developing according to plans, Beriplast® P Combi-Set has the potential to become one of Nycomed's top ten selling products within a few years."

Beriplast® P Combi-Set has for some years been marketed in five European markets (Austria, France, Germany, Greece and Portugal). As a consequence of the agreement, Nycomed will be launching the product on a pan-European level from 2005.

About ZLB Behring

ZLB Behring is a global leader in the plasma protein biotherapeutics industry. Dedicated to improving the quality of life for patients throughout the world, ZLB Behring provides safe and effective plasma-derived and recombinant products and offers patients a wide range of related services.

The company's broad portfolio of life-saving therapeutics are used in the treatment of individuals with haemophilia and other bleeding disorders, immune deficiency disorders and inherited emphysema; the prevention of haemolytic diseases for the newborn; cardiac surgery patients; and shock and burn victims.

Nycomed Group
Corporate Communications

Langebjerg 1
PO Box 88
4000 Roskilde
Denmark

Telephone:
(+45) 46 77 11 11
Telefax:
(+45) 46 77 42 72

Internet:
www.nycomed.com

Additionally, ZLB Behring operates one of the world's largest, fully-owned plasma collection networks. ZLB Behring is a subsidiary of CSL Limited, a biopharmaceutical company, which operates worldwide from its headquarters in Melbourne, Australia.

For more information, visit www.zlbbehring.com

About Nycomed

Nycomed is a pharmaceutical company differentiating itself by its European focus. The company's capabilities include product sourcing, late-stage clinical trials, registration, pricing and reimbursement negotiation and product life-cycle management. Dedicated sales teams target general practitioners, hospital specialists and pharmacists.

With 2,800 people, mostly in marketing & sales, Nycomed covers 19 European markets including the Russia/CIS. Products are also exported to other countries including Japan and the USA. Nycomed is a privately-owned company with 2003 revenue of € 635.5 million.

Further information is available on: www.nycomed.com

For further information:

Håkan Björklund, CEO
Nycomed
Phone: (+45) 46 77 11 11

Christoffer Jensen, VP Communications
Nycomed
Phone: (+45) 46 77 11 12
Mobile: (+45) 22 43 69 44

Mimi Garner, Senior Director Corporate Communications
ZLB Behring
Phone: (+1) 610 878 4155